Objective: To report the incidence and risk factors of urosepsis after ureteroscopic lithotripsy (URSL). Patients and Methods: We retrospectively reviewed 1,421 patients who underwent URSL for ureteral calculi between July 2015 and June 2018 at our department to identify factors predicting postoperative urosepsis. Demographic characteristics, clinical data, operative information, and complications were compared, and risk factors of postoperative urosepsis were identified and analyzed. Results: Of the 1,421 patients treated with URSL using holmium: yttrium-aluminum-garnet laser, 12 (0.8%) developed a urosepsis after operation. The positive preoperative multidrug resistance (MDR) urine culture and operative duration were statistically different between those who did and did not develop a urosepsis (4.61 vs. 25%, p = 0.017; 70 vs. 62 min, p < 0.001). However, patient age, sex, body mass index, diabetes mellitus, history of urolithiasis, positive preoperative urine cultures, stone size and location, degree of hydronephrosis, and prior stent placement were similar in 2 groups. Multivariate analysis revealed that positive preoperative MDR urine culture and long operation duration significantly increased the risk of postoperative urosepsis (OR 5.090, 95% CI 1.312–19.751, p = 0.019; OR 1.034, 95% CI 1.004–1.063; p = 0.024). Matched-pair analysis demonstrated that positive preoperative MDR urine culture and operation duration were significantly associated with postoperative urosepsis (OR 15.77, 95% CI 1.033–240.7, p = 0.047; OR 1.087, 95% CI 1.011–1.169, p = 0.025). Conclusions: Patients with positive preoperative MDR urine culture or long operation duration had a higher risk of developing urosepsis after URSL. When treating patients who present with positive preoperative MDR urine culture or long operation duration, urologists should be vigilant and aware of the potential risk of urosepsis.

Keywords:
Ureteroscopy, Lithotripsy, Urosepsis, Complication, Risk factors
1.
Raheem OA, Khandwala YS, Sur RL, Ghani KR, Denstedt JD. Burden of Urolithiasis: Trends in Prevalence, Treatments, and Costs.
Eur Urol Focus
. 2017 Feb;3(1):18–26.
2.
Wetherell DR, Ling D, Ow D, Koonjbeharry B, Sliwinski A, Weerakoon M, et al. Advances in ureteroscopy.
Transl Androl Urol
. 2014 Sep;3(3):321–7.
3.
Yang C, Li S, Cui Y. Comparison of YAG Laser Lithotripsy and Extracorporeal Shock Wave Lithotripsy in Treatment of Ureteral Calculi: A Meta-Analysis.
Urol Int
. 2017;98(4):373–81.
4.
Cui X, Ji F, Yan H, Ou TW, Jia CS, He XZ, et al. Comparison between extracorporeal shock wave lithotripsy and ureteroscopic lithotripsy for treating large proximal ureteral stones: a meta-analysis.
Urology
. 2015 Apr;85(4):748–56.
5.
Kozyrakis DG, Kratiras ZK, Perikleous SK, Zarkadas AP, Chatzistamoy SE, Karagiannis DK, et al. How Effective Is Retrograde Semirigid and Flexible Ureteroscopic Lithotripsy for the Treatment of Large Ureteral Stones Equal of or Greater than 15 mm? Results from a Single Center.
Urol Int
. 2019;103(1):74–80.
6.
Somani BK, Giusti G, Sun Y, Osther PJ, Frank M, De Sio M, et al. Complications associated with ureterorenoscopy (URS) related to treatment of urolithiasis: the Clinical Research Office of Endourological Society URS Global study.
World J Urol
. 2017 Apr;35(4):675–81.
7.
Scotland KB, Lange D. Prevention and management of urosepsis triggered by ureteroscopy.
Res Rep Urol
. 2018 Jul;10:43–9.
8.
Mitsuzuka K, Nakano O, Takahashi N, Satoh M. Identification of factors associated with postoperative febrile urinary tract infection after ureteroscopy for urinary stones.
Urolithiasis
. 2016 Jun;44(3):257–62.
9.
Senocak C, Ozcan C, Sahin T, Yilmaz G, Ozyuvali E, Sarikaya S, et al. Risk Factors of Infectious Complications after Flexible Uretero-renoscopy with Laser Lithotripsy.
Urol J
. 2018 Jul;15(4):158–63.
10.
Nevo A, Mano R, Baniel J, Lifshitz DA. Ureteric stent dwelling time: a risk factor for post-ureteroscopy sepsis.
BJU Int
. 2017 Jul;120(1):117–22.
11.
Blackmur JP, Maitra NU, Marri RR, Housami F, Malki M, McIlhenny C. Analysis of Factors’ Association with Risk of Postoperative Urosepsis in Patients Undergoing Ureteroscopy for Treatment of Stone Disease.
J Endourol
. 2016 Sep;30(9):963–9.
12.
Fan S, Gong B, Hao Z, Zhang L, Zhou J, Zhang Y, et al. Risk factors of infectious complications following flexible ureteroscope with a holmium laser: a retrospective study.
Int J Clin Exp Med
. 2015 Jul;8(7):11252–9.
13.
Moses RA, Ghali FM, Pais VM Jr, Hyams ES. Unplanned Hospital Return for Infection following Ureteroscopy-Can We Identify Modifiable Risk Factors?
J Urol
. 2016 Apr;195(4 Pt 1):931–6.
14.
Legemate JD, Wijnstok NJ, Matsuda T, Strijbos W, Erdogru T, Roth B, et al. Characteristics and outcomes of ureteroscopic treatment in 2650 patients with impacted ureteral stones.
World J Urol
. 2017 Oct;35(10):1497–506.
15.
Geraghty R, Abourmarzouk O, Rai B, Biyani CS, Rukin NJ, Somani BK. Evidence for Ureterorenoscopy and Laser Fragmentation (URSL) for Large Renal Stones in the Modern Era.
Curr Urol Rep
. 2015 Aug;16(8):54.
16.
Karakan T, Kilinc MF, Demirbas A, Hascicek AM, Doluoglu OG, Yucel MO, et al. Evaluating Ureteral Wall Injuries with Endoscopic Grading System and Analysis of the Predisposing Factors.
J Endourol
. 2016 Apr;30(4):375–8.
17.
Zhong W, Leto G, Wang L, Zeng G. Systemic inflammatory response syndrome after flexible ureteroscopic lithotripsy: a study of risk factors.
J Endourol
. 2015 Jan;29(1):25–8.
18.
Zowawi HM, Harris PN, Roberts MJ, Tambyah PA, Schembri MA, Pezzani MD, et al. The emerging threat of multidrug-resistant Gram-negative bacteria in urology.
Nat Rev Urol
. 2015 Oct;12(10):570–84.
19.
Uchida Y, Takazawa R, Kitayama S, Tsujii T. Predictive risk factors for systemic inflammatory response syndrome following ureteroscopic laser lithotripsy.
Urolithiasis
. 2018 Aug;46(4):375–81.
20.
Sohn DW, Kim SW, Hong CG, Yoon BI, Ha US, Cho YH. Risk factors of infectious complication after ureteroscopic procedures of the upper urinary tract.
J Infect Chemother
. 2013 Dec;19(6):1102–8.
21.
Patel N, Shi W, Liss M, Raheem O, Wenzler D, Schallhorn C, et al. Multidrug resistant bacteriuria before percutaneous nephrolithotomy predicts for postoperative infectious complications.
J Endourol
. 2015 May;29(5):531–6.
22.
Martov A, Gravas S, Etemadian M, Unsal A, Barusso G, D’Addessi A, et al.; Clinical Research Office of the Endourological Society Ureteroscopy Study Group. Postoperative infection rates in patients with a negative baseline urine culture undergoing ureteroscopic stone removal: a matched case-control analysis on antibiotic prophylaxis from the CROES URS global study.
J Endourol
. 2015 Feb;29(2):171–80.
23.
Korets R, Graversen JA, Kates M, Mues AC, Gupta M. Post-percutaneous nephrolithotomy systemic inflammatory response: a prospective analysis of preoperative urine, renal pelvic urine and stone cultures.
J Urol
. 2011 Nov;186(5):1899–903.
24.
Chew BH, Flannigan R, Kurtz M, Gershman B, Arsovska O, Paterson RF, et al. A Single Dose of Intraoperative Antibiotics Is Sufficient to Prevent Urinary Tract Infection During Ureteroscopy.
J Endourol
. 2016 Jan;30(1):63–8.
25.
Mariappan P, Smith G, Moussa SA, Tolley DA. One week of ciprofloxacin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: a prospective controlled study.
BJU Int
. 2006 Nov;98(5):1075–9.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.